Gloria Ravegnini
Overview
Explore the profile of Gloria Ravegnini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
2271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mezzapesa F, Dondi G, Coada C, De Leo A, Terlizzi F, Strigari L, et al.
Int J Gynecol Cancer
. 2025 Feb;
:101634.
PMID: 39955191
Objective: This study aimed to describe 2 types of endometriosis-associated ovarian cancer: those with transitional elements (atypical endometriosis and borderline tumors) termed endometriosis-correlated or incidental benign endometriosis vs ovarian cancer...
2.
Gatti M, Beretti F, Ravegnini G, Gorini F, Ceneri E, Bertucci E, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684214
Mesenchymal stromal cells (MSCs) and their secretome show intrinsic antitumor properties, however, the anti-cancer effects of MSCs remain debated and depend on the cancer type or model. MSCs derived from...
3.
Ferioli M, Perrone A, De Iaco P, Zamfir A, Ravegnini G, Buwenge M, et al.
Curr Oncol
. 2024 Oct;
31(10):6433-6444.
PMID: 39451782
Electrochemotherapy (ECT) is an emerging therapeutic approach gaining growing interest for its potential immunomodulatory effects in cancer treatment. This narrative review systematically examines the current state of knowledge regarding the...
4.
Di Vito A, Mandrone M, Chiocchio I, Gorini F, Ravegnini G, Coschina E, et al.
Plants (Basel)
. 2024 May;
13(9).
PMID: 38732416
Novel treatments in gastrointestinal stromal tumors (GISTs) are essential due to imatinib resistance and the modest results obtained with multi-target tyrosine kinase inhibitors. We investigated the possibility that the hydroalcoholic...
5.
Santoro M, Zybin V, Coada C, Mantovani G, Paolani G, Di Stanislao M, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672651
Background: The accurate discrimination of uterine leiomyosarcomas and leiomyomas in a pre-operative setting remains a current challenge. To date, the diagnosis is made by a pathologist on the excised tumor....
6.
Ravegnini G, Gorini F, Coada C, De Leo A, de Biase D, Di Costanzo S, et al.
Cancer Sci
. 2024 Jan;
115(3):883-893.
PMID: 38196275
Endometrial cancer (EC) is the most prevalent gynecological cancer in high-income countries. Its incidence is skyrocketing due to the increase in risk factors such as obesity, which represents a true...
7.
Sarco/endoplasmic reticulum calcium ATPase 3 (SERCA3) expression in gastrointestinal stromal tumours
Adle-Biassette H, Ricci R, Martin A, Martini M, Ravegnini G, Kaci R, et al.
Pathology
. 2024 Jan;
56(3):343-356.
PMID: 38184384
Accurate characterisation of gastrointestinal stromal tumours (GIST) is important for prognosis and the choice of targeted therapies. Histologically the diagnosis relies on positive immunostaining of tumours for KIT (CD117) and...
8.
Coada C, Ravegnini G, Perrone A
Int J Gynecol Cancer
. 2023 Dec;
34(1):176.
PMID: 38097347
No abstract available.
9.
Coada C, Santoro M, Zybin V, Di Stanislao M, Paolani G, Modolon C, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760503
Background: Current prognostic models lack the use of pre-operative CT images to predict recurrence in endometrial cancer (EC) patients. Our study aimed to investigate the potential of radiomic features extracted...
10.
Coada C, Dondi G, Ravegnini G, Di Costanzo S, Tesei M, Fiuzzi E, et al.
J Gynecol Oncol
. 2023 Sep;
34(6):e82.
PMID: 37743060
Objective: Neoadjuvant chemotherapy (NACT) represents a treatment option in patients with advanced epithelial ovarian cancer (AEOC) who are not good candidates for primary debulking surgery. Usually, 3 cycles of chemotherapy...